As health experts continue to debate whether the popular blood thinner Pradaxa used by atrial fibrillation patients has dangerous internal bleeding risks, hundreds of patients affected are moving forward with lawsuits in a special federal court.
Now, the judge overseeing those cases has ordered the maker of the drug to uncover another layer of secrecy surrounding its design and sale: how employees were compensated in relation to Pradaxa sales and safety.
After more than a year of reviewing safety tests, the FDA has stated Pradaxa is no more dangerous than Coumadin or warfarin when it comes to internal bleeding risks. However, experts point out that those traditional drugs have antidotes to stop internal bleeding when it occurs.
The Institute for Safe Medication Practices, on the other hand, has ranked drugs like Pradaxa as some of the most dangerous available, and cautioned that Pradaxa bleeding is around 5 times as likely to cause death than bleeding from Coumadin.
Researchers at the University of Illinois at Chicago also recently warned that the data relied upon by the FDA may be flawed, and Pradaxa bleeding risks may be higher than predicted.
Already, hundreds of patients have filed a Pradaxa lawsuit alleging the drug caused internal bleeding. With so many, cases have been consolidated to a special federal court in Illinois.
Now, the judge overseeing those cases has ordered Boehringer Ingelheim, the maker of Pradaxa, to disclose how employees were reviewed and compensated in relation to the design, approval, promotion, sales and safety regulation of the drug.
Lawyers are still helping those affected by bleeding file a Pradaxa lawsuit. If you or a loved one have been hospitalized, it is important to learn your legal options. Due to the specialized nature of federal drug injury cases, DrugRisk only recommends lawyers who have already handled Pradaxa lawsuits.
Contact us today for more information on the research, side effects and litigation news related to Pradaxa, or to speak with a lawyer.